A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU-002)
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease
Sponsor: Alzheimer's Association
Listed as NCT06647498, this PHASE2/PHASE3 trial focuses on Alzheimers Disease and Alzheimers Disease, Familial and remains actively recruiting participants. Sponsored by Alzheimer's Association, it has been updated 6 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE2/PHASE3
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Dec 2024 — May 2025 [monthly]
Recruiting PHASE2/PHASE3
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Nov 2024 — Dec 2024 [monthly]
Not Yet Recruiting PHASE2/PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alzheimer's Association
- Eli Lilly and Company
- GHR Foundation
- National Institute on Aging (NIA)
- Private Donors
- Washington University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .